Bayer: $250m investment in new plant
(CercleFinance.com) - Bayer has announced a $250m investment in a new cell therapy manufacturing facility in Berkeley, California, US.
The new plant will supply cell therapy products for late-stage clinical trials and future launches of BlueRock Therapeutics' bemdaneprocel (BRT-DA01), an investigational cell therapy currently under evaluation for the treatment of Parkinson's disease.
This new facility ensures that Bayer's investment in cell therapies can become a reality for patients worldwide, it said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The new plant will supply cell therapy products for late-stage clinical trials and future launches of BlueRock Therapeutics' bemdaneprocel (BRT-DA01), an investigational cell therapy currently under evaluation for the treatment of Parkinson's disease.
This new facility ensures that Bayer's investment in cell therapies can become a reality for patients worldwide, it said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.